BioNexus Gene Lab (BGLC) Assets Average (2019 - 2026)

BioNexus Gene Lab has disclosed Assets Average across 8 years of filings, most recently posting $8.9 million for Q2 2026.

• In Q2 2026, Assets Average fell 6.0% year-over-year to $8.9 million; the TTM figure through Jun 2026 stood at $8.9 million (down 6.0% YoY), while the FY2025 annual figure was $9.8 million, down 9.83% from the prior year.
• Assets Average came in at $8.9 million for Q2 2026 at BioNexus Gene Lab, down from $9.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $11.4 million in Q4 2023 to a low of $8.0 million in Q2 2023.
• Average Assets Average over 5 years is $9.5 million, with a median of $9.3 million recorded in 2022.
• Year-over-year, Assets Average soared 38.64% in 2024 and decreased 23.01% in 2025.
• Over 5 years, Assets Average stood at $8.3 million in 2022, then jumped by 38.26% to $11.4 million in 2023, then dropped by 6.28% to $10.7 million in 2024, then retreated by 21.26% to $8.4 million in 2025, then rose by 5.29% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $8.9 million in Q2 2026, $9.1 million in Q1 2026, and $8.4 million in Q4 2025.